Available for eligible patients who are uninsured or cannot afford medication.
*Terms & Conditions may apply.
RUBRACA offers a dedicated team of licensed clinicians to support your practice and patients. The PEM team serves as a single point of contact to remove access barriers, helping with prior authorizations, appeals, coverage gap solutions, and adherence monitoring. To request personalized PEM support, complete the RUBRACA Enrollment Form.
COMPLETE THE RUBRACA ENROLLMENT AND COMPREHENSIVE SUPPORT FORM
Your patients may benefit from additional support such as co-pay and coverage programs to help them pay for treatment.
Enroll online
Prescribers can input patient information to help coordinate enrollment.
Patients can also provide consent and access their co-pay ID through the portal.
Download and fax the form
Once your patient has enrolled, a pharma& case manager will contact them to provide next steps for accessing treatment.
Eligibility Criteria
Eligibility Criteria
Patient Instructions
If you are an eligible, commercially insured patient, the RUBRACA co-pay card will reduce your out-of-pocket costs up to the copay program annual limitation. If you reach the maximum annual limit, you will be responsible for any additional cost.
When you use this card, you are certifying that you understand and agree to comply with the program Terms & Conditions below.
Terms & Conditions
Eligibility Criteria
| Household Size | Annual Income* |
|---|---|
| 1 | $45,180 or less |
| 2 | $61,320 or less |
| 3 | $77,460 or less |
| 4 | $93,600 or less |
| If your household has more than four members, please add $16,140* for each additional dependent member. | |
Terms & Conditions
These Terms & Conditions are effective as of 01/01/2025.
Personal progress tracking to help set and keep goals
Comprehensive information in a simple, digestible format
New weekly information to help change habits step by step
Lessons are completed at the pace of the user, and patients are able to download and print lessons to keep with them as they control their own progress.
Care Partner Corner supports and empowers care partners of men with prostate cancer, resulting in more confident care
aPC Central arms you with the knowledge, guidance, and support you need as you care for your patients
aPC Central is a resource for healthcare providers (HCPs) that includes extensive information about advanced prostate cancer (aPC) to help ensure the best possible outcomes for patients. At aPC Central, HCPs can find:
RUBRACA® (rucaparib) is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/
or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.
The duration of RUBRACA treatment prior to the diagnosis of MDS/AML ranged from < 2 months to approximately 72 months. The cases were typical of secondary MDS/
cancer therapy-related AML; in all cases, patients had received previous platinum-containing chemotherapy regimens and/
or other DNA damaging agents.
In TRITON3, MDS/AML occurred in 2 out of 201 patients (1%) with a BRCA mutation treated with RUBRACA. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.4 to 2.3 years.
If MDS/AML is confirmed, discontinue RUBRACA.
Most common adverse reactions of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON3 (≥10%, Grade 1-4) were fatigue/asthenia (61%), musculoskeletal pain (53%), nausea (51%), decreased appetite (34%), diarrhea (31%), constipation (31%), vomiting (25%), dyspnea (19%), dysgeusia (18%), edema (18%), abdominal pain (17%), dizziness (16%), weight decreased (16%), rash (13%), headache (12%), peripheral neuropathy (12%), photosensitivity reaction (12%), and urinary tract infection (10%).
Most common adverse reactions of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia (62%), nausea (52%), decreased appetite (28%), rash (27%), constipation (27%), vomiting (22%), and diarrhea (20%).
Most common laboratory abnormalities of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON2 (≥ 35%; Grade 1-4) were increased ALT (69%), decreased leukocytes (69%), decreased phosphate (68%), decreased absolute neutrophil count (62%), decreased hemoglobin (59%), increased alkaline phosphatase (44%), increased creatinine (43%), decreased lymphocytes (42%), increased triglycerides (42%), decreased platelets (40%), and decreased sodium (38%).
If concomitant administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring.
For medical information inquiries within the U.S., contact pharma& at medinfo.us@pharmaand.com.
You may report adverse events to the FDA at 1-800-FDA-1088 or www.fda.gov/
medwatch.
Alternatively, to report an adverse event or reaction, contact pharma& at pv@pharmaand.com.
To report a product complaint, contact pharma& at complaints@pharmaand.com.
for the treatment of BRCA-mutated mCRPC1
Learn more about the updated indication in the full Prescribing Information
ARPI, androgen receptor pathway inhibitor; BRCA, BReast CAncer gene; mCRPC, metastatic castration-resistant prostate cancer;
PARPi, poly (adenosine diphosphate-ribose) polymerase inhibitor.
